Company News

ImmuneOnco Listed on the Main Board of the HKEX

(Hong Kong, September 5th, 2023) ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (stock code: 01541.HK), today listed on the Main Board of The Stock Exchange of Hong Kong Limited (the “Hong Kong Stock Exchange”).


At the listing ceremony,Dr. Tian Wenzhi,Chairman of the Board, Chief Executive Officer, Chief Scientific Officer ,representatives of the management of ImmuneOnco, as well as government and investment institution representatives and other guests, together sounded the gong for its listing in HKEx. Representatives from all sectors of the society, especially the industry and investment institutions, expressed their sincere wishes to and firm confidence in the development of ImmuneOnco after the listing.